Zentiva to Be Bought by GTCR in $4.8B Agreement
The pharmaceutical industry has seen another major shift as Zentiva, one of Europe’s leading generic drugmakers, is set to be acquired by private equity firm GTCR in a deal valued at $4.8 billion. This transaction highlights the rising demand for affordable medicines, strategic investments in healthcare, and the growing importance of innovative financing in the…